Q1: What is BioRegulator Research?

BioRegulator Research is an independent scientific publishing platform dedicated to reviewing and communicating the peer-reviewed literature on bioregulator peptides and related compounds. We are not affiliated with any commercial vendor, pharmaceutical company, or clinical practice. Our mission is to make rigorous, evidence-based peptide science accessible to researchers, students, medical professionals, and informed enthusiasts. All content is produced by qualified researchers and reviewed against strict editorial standards before publication.

Q2: Is this medical advice?

No. Nothing on BioRegulator Research constitutes medical advice, diagnosis, or treatment recommendations. All content is provided for educational and informational purposes only, summarizing findings from published scientific literature. Peptide compounds discussed on this site are not approved drugs (unless explicitly noted), and their use in humans outside of clinical trial contexts may be illegal in many jurisdictions. Always consult a qualified medical professional before making any health-related decisions. The research we discuss is often preclinical — conducted in cells or animals — and may not apply to human physiology.

Q3: Who is this website for?

BioRegulator Research is designed for individuals with a serious interest in the science of peptides and bioregulation — including academic and clinical researchers studying peptide pharmacology, medical professionals seeking to understand the mechanistic basis of peptide-related treatments, graduate students and postdoctoral researchers in biochemistry and related fields, and highly informed enthusiasts who approach the subject with scientific literacy. Our content assumes a baseline familiarity with biology and chemistry. We do not produce beginner-level health content, and we do not recommend or endorse the use of any compounds for personal health purposes.

Q4: What are bioregulator peptides?

Bioregulator peptides are a class of short-chain peptides (typically 2-4 amino acids in length) that were developed and extensively studied by Prof. Vladimir Khavinson and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg, Russia, beginning in the 1970s. Their proposed mechanism of action involves binding to DNA regulatory regions and modulating gene expression in a tissue-specific manner, effectively normalizing age-related changes in protein synthesis. Examples include Epithalon (pineal bioregulator), Thymalin (thymic bioregulator), and Cortagen (brain/neuronal bioregulator). While the body of research is substantial — particularly from Russian-language journals — the broader international research community has only recently begun engaging with this literature in depth.

Q5: How do you select your research sources?

We draw exclusively from peer-reviewed scientific literature indexed in databases such as PubMed (MEDLINE), Scopus, Web of Science, and Google Scholar. We prioritize primary research — original experimental studies — over secondary reviews, though we do reference high-quality systematic reviews and meta-analyses where available. We do not cite commercial white papers, product marketing materials, forum posts, or unverified claims. Where we reference Russian-language research, we use published English-language translations or verified summaries. All sources are cited with full bibliographic details so readers can access and evaluate primary materials independently.

Q6: Are peptides legal?

The legal status of peptides varies significantly by country, compound, and intended use. Some peptides (such as insulin, semaglutide, and various growth hormone products) are approved pharmaceutical drugs regulated by health authorities in most countries. Others are classified as research chemicals with no approved human use — their sale is typically permitted only for laboratory research purposes, not for human consumption. In some jurisdictions, certain peptides are listed as controlled substances. We strongly recommend consulting the applicable regulatory authority in your country before acquiring or using any peptide compound. BioRegulator Research does not sell, source, or recommend any peptide products, and we do not provide guidance on acquisition.

Q7: What is the difference between a peptide and a protein?

The distinction is primarily one of size and complexity. Both peptides and proteins are chains of amino acids connected by peptide bonds. Peptides are generally defined as chains of fewer than 50 amino acids, while proteins contain 50 or more amino acid residues and typically fold into complex three-dimensional structures required for their function. In practice, the boundary is not absolute — some molecules in the 30-50 amino acid range are referred to interchangeably as peptides or small proteins. Bioregulator peptides, being just 2-4 amino acids, are at the extreme short end of the spectrum. Their small size contributes to their proposed ability to penetrate cell membranes and interact directly with DNA regulatory elements.

Q8: What does “for research purposes only” mean?

“For research purposes only” is a designation applied to compounds that have not received regulatory approval for human use by agencies such as the FDA (United States), EMA (European Union), or Health Canada. When applied to peptides, it means the compound is legally available only for use in scientific research contexts — laboratory studies, in vitro experiments, or preclinical animal research — and not for human administration. This designation is not a loophole or a marketing phrase; it carries genuine legal and regulatory significance. Content on BioRegulator Research discusses compounds in the context of published scientific research and does not encourage or facilitate their use outside of approved research protocols.

Q9: How often is content updated?

New research articles and reviews are published on a rolling basis as significant findings emerge in the literature. All existing content undergoes a comprehensive review on a quarterly schedule — approximately every three months — to incorporate new published research, correct any factual inaccuracies identified since publication, update citations to include more recent sources, and revise interpretations where new evidence warrants. Each article displays a “Last Reviewed” date so readers can assess how current the information is. We consider keeping our content scientifically current to be a core editorial obligation.

Q10: How do I get the free research guide?

You can access our free introductory research guide by visiting the Free Guide page. The guide provides a structured introduction to bioregulator peptide science, covering the foundational research from the St. Petersburg Institute, key compounds and their studied mechanisms, and a curated reading list for those wishing to explore the primary literature in greater depth. It is available as an instant digital download upon email registration and is provided at no cost as part of our mission to make this research accessible to a broader audience.

Q11: Can I contribute research or suggest topics?

Yes — we welcome suggestions and contributions from qualified researchers. For topic suggestions, you can submit a request through our Contact page. For those interested in contributing original research reviews or articles, please review our Contributor Guidelines on the Research Team page before reaching out. All guest contributors must hold relevant academic or professional credentials, disclose any conflicts of interest, and agree to our editorial review process. We do not publish sponsored content, promotional pieces, or articles with commercial intent.

Q12: What is your editorial policy?

Our editorial policy requires that all factual claims be supported by citations to peer-reviewed research. We distinguish clearly between established findings, emerging evidence, and speculative interpretations. Where evidence is limited, conflicted, or predominantly preclinical, we state this explicitly rather than overstating certainty. All content is reviewed by at least one additional qualified team member before publication. We correct errors promptly and transparently — corrections are noted at the top of affected articles with the date of revision. We do not remove or alter published content to suppress unfavorable findings.

Q13: How do you handle conflicts of interest?

BioRegulator Research operates without commercial affiliations. We do not accept advertising, sponsored posts, affiliate commissions, or payments from peptide vendors, supplement companies, or pharmaceutical manufacturers. Team members and contributors are required to disclose any financial relationships with commercial entities in the peptide space. We do not write about, recommend, or link to specific product vendors. If a conflict of interest is identified in a contributor’s background, the conflict is either disclosed prominently within the article or the contributor is excluded from covering that topic. Our financial sustainability depends exclusively on reader support, which we believe is the most integrity-preserving model for an independent research publication.

Q14: What are the most studied peptides?

The peptides with the largest bodies of published research include:

• Epithalon — pineal bioregulator with extensive telomere and aging research (Khavinson et al.)
• BPC-157 — body-protective compound studied for gastrointestinal healing and tissue repair
• Thymosin Alpha-1 (Ta1) — immune modulation, approved in some countries for hepatitis B/C
• TB-500 / Thymosin Beta-4 — studied for actin regulation, wound healing, and cardiac tissue
• GLP-1 analogs — semaglutide, liraglutide — among the most clinically advanced peptide therapeutics
• GHRH/GHRP combinations — Sermorelin, CJC-1295, Ipamorelin — GH secretagogue research
• GHK-Cu — copper tripeptide, wound healing and skin repair research

Q15: Where can I find peer-reviewed peptide research?

The best freely accessible databases for peer-reviewed peptide research include:

• PubMed (pubmed.ncbi.nlm.nih.gov) — the primary index for biomedical literature; most comprehensive for peptide pharmacology
• PubMed Central (PMC) — free full-text access to a large subset of PubMed articles
• Google Scholar (scholar.google.com) — useful for finding older and international literature, including Russian-language research
• Semantic Scholar (semanticscholar.org) — AI-assisted literature discovery with citation analysis
• ResearchGate (researchgate.net) — researchers often share full-text PDFs of their own publications

For bioregulator-specific research, searching “Khavinson” on PubMed will surface the core body of work from the St. Petersburg Institute. Our research articles also include curated citation lists to guide deeper exploration.